Loading
Life sciences · Journal article
Scientific Reports · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Composite metabolic indices such as CMI and TyG-BMI are used for cardiometabolic-risk prediction, yet evidence linking integrated glucose–lipid-obesity burden to benign prostatic hyperplasia (BPH) remains limited. This study constructed the novel glucose–lipid metabolic obesity index (GLMOI) and examined the association between its cumulative average and BPH incidence among Chinese middle-aged and older men. Based on the CHARLS database, 2413 men aged ≥ 45 years with complete 2011–2015 laboratory data were included. Cox proportional-hazards models were used to evaluate the association between quartiled cumulative average GLMOI and incident BPH. Multivariable adjustment, dose-response, trajectory, subgroup and sensitivity analyses (including propensity-score matching) were performed. During 4-year follow-up, 248 new BPH cases occurred. After full adjustment, higher cumulative average GLMOI was related to elevated BPH risk ( P for trend = 0.031; Q4 vs Q1: HR = 1.437, 95% CI 0.960–2.152). Per 1-SD GLMOI increment yielded a 15.2% higher BPH risk (HR = 1.152, 95% CI 1.013–1.310), indicating a dose-response relationship. GLMOI-fluctuating groups showed significantly higher BPH risk, while persistently high GLMOI only conferred marginal risk elevation. No significant subgroup-interaction was detected, though nominally stronger associations were seen in urban residents and participants without hypertension or diabetes. Cumulative average GLMOI combining glucose–lipid and obesity indicators is independently associated with incident BPH in Chinese middle-aged and older men. Metabolic fluctuation, rather than sustained high GLMOI, may increase BPH risk. GLMOI could serve as a low-cost marker for population-level BPH risk stratification.